Thesis
Seralutinib's NDA path hinges on FDA accepting a missed primary endpoint dataset supported by robust secondary and subgroup signals
Seralutinib is an inhaled PDGFR/FGFR/CSF1R kinase inhibitor targeting PAH in Functional Class II/III patients on background therapy. The thesis resolves at the Pre-NDA Type B meeting and subsequent NDA filing acceptance — if FDA accepts the PROSERA totality-of-evidence argument, approval becomes plausible; if not, the program ends. The primary regulatory risk is FDA declining to accept a primary endpoint miss, with Liquidia's approved YUTREPIA and established prostacyclin/ERA combinations already occupying the treatment landscape.
Focus
Type C FDA meeting on seralutinib regulatory path
Jun 2026
Bull
A productive Pre-NDA Type B meeting results in FDA accepting the totality-of-evidence framework, including the near-miss primary endpoint (p=0.0320 vs. threshold of 0.025), the highly significant NT-proBNP reduction (p=0.0002), and the compelling CTD-PAH subgroup (+37m, p=0.0104) and intermediate/high-risk subgroup (+20m, p=0.0207) signals. This alignment would clear the path for an NDA submission and a standard review cycle leading to a potential approval decision, validating the thesis that a missed primary with robust supportive data can sustain a regulatory filing.
Bear
FDA signals at the Pre-NDA meeting that the missed primary endpoint is disqualifying under its evidentiary standards for PAH, or that the secondary and subgroup data — being nominally unadjusted and not controlling for multiplicity — are insufficient to characterize a favorable benefit-risk profile. Additional failure modes include FDA requiring a new confirmatory study, raising concerns about the elevated discontinuation rate (15.0% vs. 5.8%) and adverse event profile that could weigh against approval absent a clearer efficacy anchor.
Unlock the full thesis for GOSS.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.